Abstract
Antiplatelet therapies are recommended to reduce the risk of recurrent stroke in patients with non-cardioembolic ischemic stroke (IS) or transient ischemic attack (TIA); however, increased risk for bleeding may limit the use of currently approved agents. Real-world data on effectiveness and safety of antiplatelet regimens are lacking. This study evaluated outpatient antiplatelet treatment patterns for secondary stroke prevention (SSP) after first hospitalization for IS/TIA among UK adults without atrial fibrillation (AF).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
